Date/Time
Date(s) - 12 May 2021
1:30 PM - 1:30 PM
BIO Technology Transfer Committee Presents:
A Discussion of Translational Research
Perspectives from Industry, Venture, and Government Agency
Overview:
Applied research aimed at stopping the spread of disease worldwide has seen breathtaking public
private mechanisms to quickly evaluate and adopt translational research platforms that have
accelerated the discovery to delivery framework in record time.
How this groundbreaking partnership works not only for the current challenges we face but for
future challenges is the focus on this BIO Technology Transfer Committee session. Speakers from
National Center for Advanced Translational Sciences, Osage University Partners, and JLABS will
review their current translational research efforts that, when taken together, will provide their
overarching objective to optimally balance the research efforts focused on advanced discovery
for medicines across the nation.
Speakers:
Sharon Semones, Advisor- Academic Search/Evaluate, Emerging Technology & Innovation,
Corporate Business Development, Eli Lilly and Company
Lili Portilla, Director of Office of Strategic Alliances, National Center for Advanced Translational
Sciences
Margalit Haber, Life Science Associate, Osage University Partners
Julie Hamill, Senior Director of External Innovation Strategy, J&J Innovation
Agenda:
• Introduction by Sharon Semones
• Comments by Speakers
• Moderated Q&A and Audience Questions
_____________________________________________________________________________
Abstract: This Panel will have three representatives spend 10 minutes each providing an
overview of opportunities for academics to utilize their program to advance research from the
bench to the clinic.
- Julie Hamill (Senior Director of External Innovation Strategy from Johnson &
Johnson Innovation) will describe the JLABS model - Margalit Haber (Life Science Associate from Osage University Partners) will describe their venture model
- Lili Portilla (Director of Office of Strategic Alliances from NCATs) will describe initiatives within their office to enable
translational research.
The panel will then be open for 30 minutes of moderated Q&A by Sharon Semones and Pete Pellerito